Phenotypes associated with this allele

• Allele Symbol: Fam210a^{tm1c(EUCOMM)Wtsi}
• Allele Name: targeted mutation 1c, Wellcome Trust Sanger Institute
• Allele ID: MGI:6159130
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Fam210a^tm1c(EUCOMM)Wtsi/Fam210a^tm1c(EUCOMM)Wtsi Tg(ACTA1-cre/Esr1*)2Kesr/0	involves: C3H * C57BL/6N * SJL	MGI:6159280
cn2	Fam210a^tm1c(EUCOMM)Wtsi/Fam210a^tm1c(EUCOMM)Wtsi Tg(CAG-cre/Esr1*)5Amc/0	involves: C57BL/6N * CBA * SJL	MGI:6159281

Genotype
MGI:6159280

cn1

• Allelic Composition: Fam210a^{tm1c(EUCOMM)Wtsi}/Fam210a^{tm1c(EUCOMM)Wtsi}; Tg(ACTA1-cre/Esr1*)2Kesr/0
• Genetic Background: involves: C3H * C57BL/6N * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

skeleton

increased osteoclast cell number ( J:261817 )

• in tamoxifen-treated mice

decreased bone mineral density ( J:261817 )

♂ • in tamoxifen-treated male mice

behavior/neurological

decreased grip strength ( J:261817 )

• in tamoxifen-treated mice

limbs/digits/tail

abnormal limb morphology ( J:261817 )

• decreased lean muscle mass in all limbs of tamoxifen-treated mice

growth/size/body

growth/size/body region phenotype ( J:261817 )

N • tamoxifen-treated mice exhibit normal body weight

immune system

increased osteoclast cell number ( J:261817 )

• in tamoxifen-treated mice

hematopoietic system

increased osteoclast cell number ( J:261817 )

• in tamoxifen-treated mice

Genotype
MGI:6159281

cn2

• Allelic Composition: Fam210a^{tm1c(EUCOMM)Wtsi}/Fam210a^{tm1c(EUCOMM)Wtsi}; Tg(CAG-cre/Esr1*)5Amc/0
• Genetic Background: involves: C57BL/6N * CBA * SJL

mortality/aging

premature death ( J:261817 )

• tamoxifen-treated mice die between 63 and 70 days after birth

skeleton

increased osteoclast cell number ( J:261817 )

• in tamoxifen-treated mice

decreased bone mineral content ( J:261817 )

• in tamoxifen-treated mice

decreased bone mineral density ( J:261817 )

• in tamoxifen-treated mice

decreased compact bone volume ( J:261817 )

• in tamoxifen-treated mice

decreased trabecular bone volume ( J:261817 )

• in tamoxifen-treated mice

decreased compact bone thickness ( J:261817 )

• in tamoxifen-treated mice

decreased bone trabecula number ( J:261817 )

• in tamoxifen-treated mice

increased bone trabecular spacing ( J:261817 )

• with increased structural model index in tamoxifen-treated mice

decreased bone ossification ( J:261817 )

• in cortical and trabecular bones of tamoxifen-treated mice

decreased bone strength ( J:261817 )

• in tamoxifen-treated mice

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:261817 )

N • tamoxifen-treated mice exhibit normal serum levels of calcium, phosphate, urea nitrogen and total protein

behavior/neurological

decreased grip strength ( J:261817 )

• in tamoxifen-treated mice

limbs/digits/tail

abnormal limb morphology ( J:261817 )

• decreased lean muscle mass in all limbs of tamoxifen-treated mice

growth/size/body

decreased body weight ( J:261817 )

• from 49 days after birth in tamoxifen-treated mice

immune system

increased osteoclast cell number ( J:261817 )

• in tamoxifen-treated mice

hematopoietic system

increased osteoclast cell number ( J:261817 )

• in tamoxifen-treated mice